Abpro Corporation (ABP)
Abpro Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Woburn, MA, US. The stock last traded at $0.52, up 0.00% on the session, giving a market capitalisation of $1.1M. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of 0.0%. Its beta of -0.00 implies it has historically moved less than the broad market.
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector. Their primary investigational drug candidates include ABP-100, designed to target breast, gastric, and colorectal cancers, and ABP-201, intended for the treatment of vascular diseases affecting the eye. The company has established strategic alliances with Abpro Bio Co. Ltd and NJCTTQ. Originally known as Abpro Corporation, the company officially changed its name to Abpro Holdings, Inc. in November 2024. Incorporated in 2004, Abpro Holdings, Inc. operates from its headquarters in Woburn, Massachusetts.
Abpro Corporation is most often compared with the following Healthcare names: